Evidence map›Paper›PMID 38652457›Full record

ArticleMicrobiology spectrum2024

Genome-scale model of

Nantia Leonidou, Lisa Ostyn, Tom Coenye, Aurélie Crabbé, Andreas Dräger

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Draft genome sequence ofMicrobiology resource announcements · 2026
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Nantia LeonidouComputational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), Eberhard Karl University of Tübingen, Tübingen, Germany.ORCID 0000-0002-0248-6679
Lisa OstynLaboratory of Pharmaceutical Microbiology (LPM), Ghent University, Ghent, Belgium.
Tom CoenyeLaboratory of Pharmaceutical Microbiology (LPM), Ghent University, Ghent, Belgium.ORCID 0000-0002-6407-0601
Aurélie CrabbéLaboratory of Pharmaceutical Microbiology (LPM), Ghent University, Ghent, Belgium.ORCID 0000-0003-3084-4418
Andreas DrägerComputational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), Eberhard Karl University of Tübingen, Tübingen, Germany.ORCID 0000-0002-1240-5553
Ghent University · BEGerman Center for Infection Research · DE

Funding

Deutsche Forschungsgemeinschaft (DFG) EXC 2124 - 390838134Deutsches Zentrum für Infektionsforschung (DZIF) 8020708703
6 · The paper itself

Abstract

Cystic fibrosis (CF), an inherited genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator gene, results in sticky and thick mucosal fluids. This environment facilitates the colonization of various microorganisms, some of which can cause acute and chronic lung infections, while others may positively impact the disease.

Indexed as

Cystic FibrosisGenome, BacterialMicrococcaceaeAnimalsGenes, EssentialHumansMicePhenotypeantimicrobial strategiesATCC 25296constraint-based modelingcystic fibrosisflux balance analysisflux variability analysisgenome-scale metabolic modelGram-positiveiRM23NLlung infectionsmathematical networkmetabolic engineeringnasal microbiomepathway analysisRothia mucilaginosa DSM20746SBML

Identifiers

PMID38652457
PMCPMC11237427
OpenAlexW4395032964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.